[HTML][HTML] The regulation and function of CD20: an “enigma” of B-cell biology and targeted therapy
G Pavlasova, M Mraz - Haematologica, 2020 - ncbi.nlm.nih.gov
The introduction of anti-CD20 monoclonal antibodies such as rituximab, ofatumumab, or
obinutuzumab improved the therapy of B-cell malignancies even though the precise …
obinutuzumab improved the therapy of B-cell malignancies even though the precise …
The regulation and function of CD20: an" enigma" of B-cell biology and targeted therapy.
G Pavlasova, M Mraz - Haematologica, 2020 - europepmc.org
The introduction of anti-CD20 monoclonal antibodies such as rituximab, ofatumumab, or
obinutuzumab improved the therapy of B-cell malignancies even though the precise …
obinutuzumab improved the therapy of B-cell malignancies even though the precise …
[PDF][PDF] The regulation and function of CD20: an “enigma” of B-cell biology and targeted therapy
G Pavlasova, M Mraz - haematologica, 2020 - researchgate.net
The approval of the anti-CD20 antibody rituximab by the Food and Drug Administration in
1997 was a conceptual breakthrough in the treatment of B-cell malignancies. Rituximab …
1997 was a conceptual breakthrough in the treatment of B-cell malignancies. Rituximab …
[PDF][PDF] The regulation and function of CD20: an “enigma” of B-cell biology and targeted therapy
G Pavlasova, M Mraz - haematologica, 2020 - academia.edu
The approval of the anti-CD20 antibody rituximab by the Food and Drug Administration in
1997 was a conceptual breakthrough in the treatment of B-cell malignancies. Rituximab …
1997 was a conceptual breakthrough in the treatment of B-cell malignancies. Rituximab …
[HTML][HTML] The regulation and function of CD20: an “enigma” of B-cell biology and targeted therapy
G Pavlasova, M Mraz - Haematologica, 2020 - haematologica.org
The introduction of anti-CD20 monoclonal antibodies such as rituximab, ofatumumab, or
obinutuzumab improved the therapy of B-cell malignancies even though the precise …
obinutuzumab improved the therapy of B-cell malignancies even though the precise …
[PDF][PDF] The regulation and function of CD20: an “enigma” of B-cell biology and targeted therapy
G Pavlasova, M Mraz - haematologica, 2020 - is.muni.cz
The approval of the anti-CD20 antibody rituximab by the Food and Drug Administration in
1997 was a conceptual breakthrough in the treatment of B-cell malignancies. Rituximab …
1997 was a conceptual breakthrough in the treatment of B-cell malignancies. Rituximab …
The regulation and function of CD20: an" enigma" of B-cell biology and targeted therapy
G Pavlasova, M Mraz - Haematologica, 2020 - pubmed.ncbi.nlm.nih.gov
The introduction of anti-CD20 monoclonal antibodies such as rituximab, ofatumumab, or
obinutuzumab improved the therapy of B-cell malignancies even though the precise …
obinutuzumab improved the therapy of B-cell malignancies even though the precise …
[HTML][HTML] The regulation and function of CD20: an “enigma” of B-cell biology and targeted therapy
G Pavlasova, M Mraz - Haematologica, 2020 - haematologica.org
The introduction of anti-CD20 monoclonal antibodies such as rituximab, ofatumumab, or
obinutuzumab improved the therapy of B-cell malignancies even though the precise …
obinutuzumab improved the therapy of B-cell malignancies even though the precise …